Intra-Cellular Therapies (ITCI)
Quick facts
| Ticker | ITCI (NASDAQ) |
|---|
Marketed products
- Caplyta · Neuroscience · revenue 900
Caplyta works by binding to the 5-hydroxytryptamine receptor 2A, which helps to regulate dopamine and serotonin levels in the brain.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: